Results 111 to 120 of about 63,889 (276)
, 2009 Pierpaolo Di Micco1,2, Paola Ferrazzi1, Luca Librè1, Loredana Mendolicchio1, Ilaria Quaglia1, Monica De Marco1, Anna Colombo1, Monica Bacci1, Lidia Luciana Rota1, Corrado Lodigiani11Thrombosis Center, Istituto Clinico Humanitas, Rozzano (MI ...
Luca Librè +3 more
core
, 2016 A 51-year-old man was diagnosed with Behçet’s disease in 2001. The patient was resistant to all immunosuppressive therapies. After 6 months of infliximab therapy, he presented to our clinic with pain and blurred vision in his right eye.
Sirel Gür Güngör +6 more
core +1 more source
The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis
JPGN Reports, EarlyView.Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke +7 more
wiley +1 more source
Treatment of severe psoriasis with infliximab
, 2008 JA Leman, AD BurdenAlan Lyell Centre for Dermatology, Western Infirmary, Glasgow, UKAbstract: Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up ...
AD Burden, JA Leman
core
JPGN Reports, EarlyView.Abstract Commercial payers and pharmacy benefit managers use site‐of‐care and specialty drug distribution policies (including white bagging and brown bagging) that can redirect infusion‐based biologic therapies from hospital outpatient departments to alternate settings.
Brad Pasternak
wiley +1 more source
Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center
JEADV Clinical Practice, EarlyView.ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres +4 more
wiley +1 more source
, 2014 Burak Turgut,1 Kenan Eren,1 Mehmet Mustafa Akin,2 Tamer Demir,1 Sabiha Kobat1 1Department of Ophthalmology, School of Medicine, Firat University, Elaziğ, Turkey; 2Department of Pathology, School of Medicine, Firat University, Elaziğ, Turkey Background ...
Turgut B +4 more
core
JEADV Clinical Practice, EarlyView.This post‐hoc analysis of the Greek real‐world ReSOLVE study compared clinical and patient‐reported outcomes by body weight (< 100 kg vs. ≥ 100 kg) and BMI over 52 weeks. Patients ≥ 100 kg showed delayed PASI and sPGA responses at W24 and W52, while BMI had little impact. Quality‐of‐life improvements were substantial, though early gains were smaller in
Pantelis Panagakis +12 more
wiley +1 more source
Profile of infliximab in the treatment of pediatric Crohn’s disease
, 2015 Jaroslaw Kierkus,1 Edyta Szymanska,2 Grzegorz Oracz,1 Anna Wiernicka,1 Maciej Dadalski1 1Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, 2Department of Pediatrics, Nutrition and Metabolic Disorders, The Children’s ...
Szymanska E +4 more
core
Mass Spectrometry Reviews, EarlyView.ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley +1 more source